Keybanc Upgrades InnovAge Holding to Overweight, Announces $13 Price Target

Innovus Pharmaceuticals, Inc.

Innovus Pharmaceuticals, Inc.

INNV

0.00

Keybanc analyst Matthew Gillmor upgrades InnovAge Holding (NASDAQ: INNV) from Sector Weight to Overweight and announces $13 price target.